Otonomy OTO-313 — Treatment of Tinnitus

#271
MrB9 said:
I was accepted for the trial, but never followed up because I thought I might have an experience like yours Chris. But, I now face the obvious risk that it does work and i'm outside the window for inclusion.

I hadn't checked this thread in months since I was considering the trial. My tinnitus gets worse some days and better on others. Recently, was considering calling the ENT to see if I would still be able to be included. Not so sure now after reading your post.
Click to expand...
If you can wait until @ChrisBoyMonkey goes back in to check whether he got the real drug or placebo. If he got placebo you should definitely do the trial.
 
#272
Looks like the stock price jumped 60% between late December and now. They have several drugs in the pipeline so I'm not sure what would have been behind the sudden interest. Only thing I can see that triggered this was an analyst set them to "outperform" back on December 23rd.
 
#275
Candy said:
Quick question, how's OTO-313 progressing? I know there's a trial but do we have any initial insights?
Click to expand...

A Phase 1/2 trial, evaluating safety and exploratory efficacy measures of OTO-313 is underway, with results expected in the second quarter of 2020.

Actual Study Start Date: April 4, 2019
Estimated Primary Completion Date: May 2020

OTO-313: Enrollment in Phase 1/2 Clinical Trial in Tinnitus is Ongoing with Results Expected in the Second Quarter of 2020. Otonomy has successfully completed the initial safety cohort of this randomized, double-blind, placebo-controlled trial, and is enrolling approximately 50 patients with persistent tinnitus in the exploratory efficacy study cohort. OTO-313 is a sustained-exposure formulation of the potent and selective NMDA receptor antagonist gacyclidine. source
 
#279
I'm quite wary of this product for chronic tinnitus once I read about the history of AM-101 and learned more about the mechanism of action...I think it could help in the acute phases but as we saw with Chris once you're out of the "acute window" you run the risk of altering your GABA in a detrimental way that could lead to worsening.

I would not get this myself personally. Possibly if I had a spike but I think we might have the Hough Pill by then to pop if need be.
 
#280
Candy said:
Thank you @serendipity1996... Does anyone have any hopes for this product?
Click to expand...

I am not very hopeful, you can read the paper that lead to the development of the drug here:

https://www.tinnitustalk.com/threads/otonomy-oto-313-—-treatment-of-tinnitus.26092/#post-407832

Re-reading it now, it just doesn't seem that promising.

However, OTO-413 looks very interesting, and we should hear results back about that the same time the results for OTO-313 are in. Otonomy also seems to have a lot of stuff in the pipeline:

https://www.otonomy.com/pipeline/

I'm optimistic that sometime within the next 5 years we'll have something that will cure or partially cure tinnitus.
 
#281
patorjk said:
I am not very hopeful, you can read the paper that lead to the development of the drug here:

https://www.tinnitustalk.com/threads/otonomy-oto-313-—-treatment-of-tinnitus.26092/#post-407832

Re-reading it now, it just doesn't seem that promising.

However, OTO-413 looks very interesting, and we should hear results back about that the same time the results for OTO-313 are in. Otonomy also seems to have a lot of stuff in the pipeline:

https://www.otonomy.com/pipeline/

I'm optimistic that sometime within the next 5 years we'll have something that will cure or partially cure tinnitus.
Click to expand...
OTO-6xx is also the only one i see that will address "severe hearing loss." I'm extremely curious about what's different about their approach to tackle severe cases.
 
#284
FGG said:
OTO-6xx is also the only one i see that will address "severe hearing loss." I'm extremely curious about what's different about their approach to tackle severe cases.
Click to expand...
... I bet they'll just recycle some gamma-secretase inhibitor, nothing new. But if they eventually come up with a new idea, well, that'd be great.
 
#285
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting

They have a few presentations during this event:

Joint presentation with AGTC related to the GJB2 gene therapy program:
  • "Ex vivo assessment of AAV capsid variant tropism and safety in rat cochlea" by Uribe et al., on January 27.
Presentations related to Otonomy's OTO-510 program for CIHL:
  • "Ex vivo evaluation of the therapeutic potential of several drug classes to prevent cisplatin mediated ototoxicity in the rat cochlea" by Mathur et al., on January 26.
  • "Evaluations of various therapeutic classes in protection against cisplatin-induced hearing loss (preclinical models)" by Tsivkovskaia et al., on January 26.
Presentations related to Otonomy's other clinical and preclinical hearing loss programs:
  • "Characterization of OTO-413, an intratympanic sustained-exposure formulation of the neurotrophic factor BDNF, in preclinical models of cochlear synaptopathy" by Tsivkovskaia et al., on January 26.
  • "Comparisons of single versus combinatorial strategies for hair cell regeneration in cochlear explants" by Uribe et al., on January 27.
Joint presentation of data with research collaborators at the University of Washington related to preclinical evaluations of an age-related hearing loss model:
  • "Age-related hearing loss in zebrafish: surprising senescence in an animal with continuous hair cell turnover" by Coffin et al., on January 28.

Nothing on the current clinical trials, that's to be expected but a few things to look for nonetheless.
 
#286
For anyone that is considering applying to the OTO-313 trial, the doctor that performs the injection can find out whether the participant got the placebo or the actual medicine, if the participant were to have an adverse event or tinnitus gets worse. Does anyone have any experience or knowledge of Gacyclidine, the paper that I read cited perfusion of 43-60 hours, so I am guessing a single shot may be relatively temporary. It appears this drug is used in the treatment of head trauma, and some other neuro treatments...

Outside of the normal risks of needle to the ear, does anyone have an opinion on why trying this drug could be bad news for future treatments?

Sidebar: I read an article advising ER docs to watch for Gacyclidine as a drug of abuse or ingredient in street drugs...
 
#287
WntRelief said:
For anyone that is considering applying to the OTO-313 trial, the doctor that performs the injection can find out whether the participant got the placebo or the actual medicine, if the participant were to have an adverse event or tinnitus gets worse. Does anyone have any experience or knowledge of Gacyclidine, the paper that I read cited perfusion of 43-60 hours, so I am guessing a single shot may be relatively temporary. It appears this drug is used in the treatment of head trauma, and some other neuro treatments...

Outside of the normal risks of needle to the ear, does anyone have an opinion on why trying this drug could be bad news for future treatments?

Sidebar: I read an article advising ER docs to watch for Gacyclidine as a drug of abuse or ingredient in street drugs...
Click to expand...
One component of OTO-313 is its "sustained exposure formulation" which was not part of the earlier study and presumably responds to the need for a practical continuous exposure delivery mechanism.
 
#289


An Audiologist on OTO-313.

(Warning, he suggests TRT at the end. :banghead:)
 
#290
aot said:
An Audiologist on OTO-313.
Click to expand...
At 3:04 (in the video) the audiologist begins to dissect the second difference between the Wenzel study and the clinical trial related to OTO-313. He seems concerned that a "single injection" (of OTO-313) would be insufficient to deliver a high-enough dose of Gacyclidine (and thereby he pretty much demonstrates that he is unaware of Otonomy's sustained delivery concept – which actually permeates the entire pipeline of the company). A single injection of the polymer containing OTO-313 is enough to provide about a month's worth of exposure (something I commented on here).

It is true that high doses of Gacyclidine were delivered – under ideal conditions – directly into the cochlea of the six study participants in the Wenzel study. But the investigation failed to deliver significant results probably because the enrolled patients were chosen on a compassionate basis (and hence they were not ideal subjects since they had exhausted all other options and were already at the chronic tinnitus stage by the time they got treated).

Disclaimer: I read the Wenzel study several times in the past (which is now +2 years ago) – so the above is stretching my memory a bit...
 
#293
Updates from today:
https://finance.yahoo.com/news/otonomy-provides-clinical-trials-development-200510830.html
They're currently hosting a conference call and webcast discussing these updates.

  • Results from Phase 3 trial of OTIVIDEX® in Ménière's disease expected in first quarter of 2021
  • Results from Phase 1/2 trial of OTO-313 in tinnitus expected in July 2020
  • Results from Phase 1/2 trial of OTO-413 in hearing loss expected in fourth quarter of 2020
  • Current capital funds operations through all clinical trial readouts
 
#296
Could someone please explain me in an simple way what is the difference between OTO-313 and FX-322?

And why are there only 10 pages in this thread (if OTO-313 is supposed to cure tinnitus) whereas FX-322 thread counts more than 150 pages?
 
#297
#299
Kam75 said:
Could someone please explain me in an simple way what is the difference between OTO-313 and FX-322?

And why are there only 10 pages in this thread (if OTO-313 is supposed to cure tinnitus) whereas FX-322 thread counts more than 150 pages?
Click to expand...
OTO-313 is for acute tinnitus only. That doesn't apply for most of us.
 

Log in or register to get the full forum benefits!

Register

Register on Tinnitus Talk for free!

Register Now

Similar threads

V
Investigation of the Effectiveness of Sound Enrichment in the Treatment of Tinnitus Due to Hearing Loss
Replies
32
Views
4K
Research News
MichaelBull
MichaelBull
N
The Efficacy of Incobotulinum Toxin A Injections for Treatment of Tinnitus
Replies
5
Views
2K
Research News
CGB
C
T
Reduction of Tinnitus with Treatment for Digestive Issues — Permea Regul Fort
Replies
3
Views
625
Alternative Treatments
Nick47
N
N
Neuracle Science Initiates Phase 1/2 Clinical Trial of NS101 for the Treatment of Hearing Loss
Replies
2
Views
2K
Research News
Street Novelist
S
I
Tinnitus Suppression with Electrical Stimulation at the Basal Contact of Cochlear Implant Electrodes: Significant Improvement in 8 of 10 Patients
Replies
2
Views
362
Research News
IYIiKe
I
Top Bottom
Back
Forums
Members
Donate
Menu